Methods and compositions for treating sleep apnea
AssigneeApnimed, Inc. (Delaware)
InventorsLawrence G. MILLER, Luigi TARANTO-MONTEMURRO, Ronald FARKAS
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions comprising a norepinephtrine reuptake inhibitor (NRI) and a mineralocorticoid antagonist and optionally a muscarinic receptor antagonist (MRA) and methods of treating sleep apnea are described herein.
Claims73
A method of treating a subject having a condition associated with pharyngeal airway collapse, the method comprising administering to a subject in need thereof an effective amount of (i) a norepinephrine reuptake inhibitor (NRI) and (ii) a mineralocorticoid antagonist.
A pharmaceutical composition comprising (i) a norepinephrine reuptake inhibitor (NRI) and (ii) a mineralocorticoid antagonist, in a pharmaceutically acceptable carrier.
A kit comprising (i) a norepinephrine reuptake inhibitor (NRI) and (ii) a mineralocorticoid antagonist, and optionally (iii) a muscarinic receptor antagonist (MRA).
A norepinephrine reuptake inhibitor (NRI) and a mineralocorticoid antagonist, and optionally a muscarinic receptor antagonist (MRA), for use in treating a subject having a condition associated with pharyngeal airway collapse.
A therapeutic combination of (i) a norepinephrine reuptake inhibitor (NRI) and (ii) a mineralocorticoid antagonist, and optionally (iii) a muscarinic receptor antagonist (MRA), for use in treating a subject having a condition associated with pharyngeal airway collapse.
Dependencies are inferred from the claim text.